APR 08, 2021 10:36 PM PDT

Patented Mix of Terpenes and CBD Has Potential to Help COVID

WRITTEN BY: Angela Dowden

Israeli-based technology firm Eybna, who specialize in isolating and testing components from the cannabis plant, say that working in conjunction with Cannasoul – another leader in cannabis research and development ­— they have discovered a combination of terpenes and CBD with the potential to manage the symptoms of COVID-19, or even to prevent infection altogether.

It’s a bold claim, but the formulation, coded named NT-VRL was made possible by teaming Eybna’s large database of cannabis ingredients with advanced data-mining and formulation design methodologies, allowing the team to research and isolate terpenes with increased anti-inflammatory properties and then to optimize their ratios.

“[It] enabled us to develop and manufacture a patented data-driven terpene formulation that is effective, safe, and synergetic,” according to Nadav Eyal, Eybna’s CEO and co-founder.

NT-VRL consists of CBD (cannabidiol) from the cannabis plant, together with terpenes from sources such as eucalyptol, beta caryophyllene, and citral. Said Eyal: “With the lack of safe anti-inflammatory pharmaceutical drugs, we decided to put our knowledge and formulation technology to the test — by demonstrating…efficacy [of this terpene / cannabinoid mix] versus dexamethasone, a steroid which has many unknown side effects. The results of this study exceeded our expectations.” 

Eybna claims the composition to be safe and effective, with the 30-ingredient natural formulation avoiding the high concentration of single ingredients, found in most pharmaceuticals. “The data-driven formulation works via various mechanisms of action in our body, making it more effective,” Eyal said, adding that NT-VRL is being peer-reviewed in 11 studies currently.

Testing is starting with Human Coronavirus strain E229 (HCoV-E229), which has similar properties to COVID-19 but is regarded as safer to work within lab settings, but Eybna plans to work with a variety of COVID-19 strains in the near future.

The company is currently expanding by opening a new facility in the United States and developing new partnerships, and their research potential is expected to continue growing rapidly. 

 

Sources: Cannabis Culture, MDPI

 

 

 

About the Author
  • I'm a journalist and author with many year's experience of writing for both a consumer and professional audience, mostly on nutrition, health and medical prescribing. My background is food science and I'm a registered nutritionist.
You May Also Like
APR 06, 2021
Infographics
Psychedelic Medicine 101
APR 06, 2021
Psychedelic Medicine 101
As clinical trials for psychedelics progress, interest in psychedelics is increasing among pharmaceutical firms, clinici ...
MAR 30, 2021
Cardiology
Looking at a Fertility Drug's Cardiac Safety
MAR 30, 2021
Looking at a Fertility Drug's Cardiac Safety
New drugs go through a long and arduous process before they can grace a doctor’s office. One of the last steps is ...
MAR 29, 2021
Cardiology
Learning More About How Stress Breaks the Heart
MAR 29, 2021
Learning More About How Stress Breaks the Heart
Scientists are learning more about what causes a real phenomenon known as broken heart syndrome, or stress-related cardi ...
APR 04, 2021
Genetics & Genomics
Gene Therapy Improves Transport in Neurons
APR 04, 2021
Gene Therapy Improves Transport in Neurons
While this approach was tested on models of eye disorders, prelimary work suggested it also has potential as a dementia ...
APR 05, 2021
Cannabis Sciences
Can Smoking Cannabis Cause Lung Cancer?
APR 05, 2021
Can Smoking Cannabis Cause Lung Cancer?
So far, there is no firm consensus on whether smoking cannabis can cause lung cancer. As cannabis smoke contains many si ...
APR 11, 2021
Genetics & Genomics
Trial Shows Personalized Cancer Vaccines are Safe
APR 11, 2021
Trial Shows Personalized Cancer Vaccines are Safe
Vaccines are mostly known as tools to prevent illness. But cancer vaccines are a bit different, and aim to treat existin ...
Loading Comments...